$VOR News
Last published 1d ago
- 1d agoVORVor Bio To Participate in 2026 Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune...
- 1w agoVORVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on November 1, 2026, the
- 1w agoVORVor Bio Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireCompleted enrollment in Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis; topline results remain on track for 1H27 Expanded telitacicept franchise into ocular myasthenia gravis with Phase 3
- 2w agoVORTelitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA NephropathyGlobeNewswireAnnualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p<0.001) 89% and 81% reductions in risk of confirmed ≥30% and ≥40% eGFR declines, respectively
- 1mo agoVORSTIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - VOR BIOPHARMA INCEarnings Call TranscriptsAll right. Good morning, everyone. I'm Stephen Woolley, one of the senior biotech analysts here at Stifel, and glad to have with us as part of the next session, Vore BioPharma. We have Dallin Murray, who is the chief com
- 1mo agoVORStifel 2026 Virtual Immunology and Inflammation Forum - VOR BIOPHARMA INCEarnings Call TranscriptsAll right. Good morning, everyone. I'm Stephen Woolley, one of the senior biotech analysts here at Stifel, and glad to have with us as part of the next session, Vore BioPharma. We have Dallin Murray, who is the chief com
- 2mo agoVORVor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia GravisGlobeNewswireTopline results from UPSTREAM MG’s 24-week primary endpoint remain on track for first half of 2027 Global Phase 3 ocular myasthenia gravis (oMG) registrational trial, UPSTREAM oMG, broadens telitacicept development
- 2mo agoVORVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation
- 2mo agoVORVor Bio To Participate in Upcoming September ConferencesGlobeNewswireBOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that management will participate in the
- 3mo agoVORVor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireEnrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in
- 3mo agoVORVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on August 1, 2026, the Compensation
- 4mo agoVORVor Bio Appoints David Zaccardelli to Board of DirectorsGlobeNewswireBOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of David Zaccardelli, Pharm.D.,
- 4mo agoVORVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on July 1, 2026, the Compensation
- 5mo agoVORTelitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in ChinaGlobeNewswireFirst regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in China Approval based on positive Phase 3 results generated by collaborator RemeGen demonstrating statistically
- 5mo agoVORTelitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in ChinaGlobeNewswireFirst and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on positive interim Phase 3 TELIGAN results generated by collaborator RemeGen and recently published in The New England
- 5mo agoVORVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation
- 5mo agoVORVor Bio to Participate in the 2026 Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a
- 6mo agoVORVor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of MedicineGlobeNewswireInterim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment Results further support the potential for telitacicept to become a
- 6mo agoVORVor Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswireEnrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of telitacicept in primary
- 6mo agoVORVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on May 1, 2026, the Compensation Committee
- 7mo agoVORVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on April 1, 2026, the Compensation
- 7mo agoVORVor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireFirst patient dosed in UPSTREAM SjD, a global Phase 3 clinical trial assessing telitacicept in primary Sjögren's disease $75 million private placement strengthens balance sheet and supports telitacicept global clinical
- 7mo agoVORVor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren's DiseaseGlobeNewswireBOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first patient in UPSTREAM
- 7mo agoVORVor Bio Announces $75 Million Private Placement with TCGXGlobeNewswireBOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase
- 7mo agoVORVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026,
- 8mo agoVORVor Bio to Participate in the 46th Annual TD Cowen Health Care ConferenceGlobeNewswireBOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1
- 10mo agoVORVor Bio Appoints RA Capital's Andrew Levin, M.D., Ph.D., and Forbion's Wouter Joustra to Board of DirectorsGlobeNewswireBOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment
- 11mo agoVORVor Bio Announces $150 Million Private PlacementGlobeNewswireBOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase
- 12mo agoVORVor Bio Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswireMultiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune DiseasesExpansion of Executive Leadership and Board Strengthens Global Development Capabilities Expected gross proceeds of
- 1y agoVORVor Bio Announces Pricing of Public Offering of $100 Million of Common StockGlobeNewswireBOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the pricing of an
- 1y agoVORVor Bio Announces Proposed Public Offering of $100 Million of Common StockGlobeNewswireBOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (NASDAQ:VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it has
- 1y agoVORTelitacicept Achieved Primary Endpoint of Reducing Proteinuria in Stage A of a Phase 3 Clinical Study for IgA Nephropathy in ChinaGlobeNewswireTreatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profile Telitacicept demonstrated a 55% reduction in
- 1y agoVORVor Bio to Participate in Upcoming Investor ConferencesGlobeNewswireBOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the following
- 1y agoVORVor Bio Appoints Jeremy Sokolove, M.D. as Chief Medical OfficerGlobeNewswireBOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Jeremy Sokolove, M.D., as
- 1y agoVORVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireBOSTON, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on October 15, 2025, the Compensation
- 1y agoVORTelitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis DataGlobeNewswireTelitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms 100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living
- 1y agoVORVor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren's DiseaseGlobeNewswireCAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to
- 1y agoVORVor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology's Kidney Week 2025GlobeNewswireCAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from Stage A of a
- 1y agoVORVor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of MedicineGlobeNewswireTrial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with telitacicept versus 32.7% with placebo Dual inhibition of BAFF and APRIL validated
- 1y agoVORTelitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren's Disease at ACR 2025GlobeNewswireTelitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-point ESSDAI (EULAR
- 1y agoVORVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 19, 2025, the
- 1y agoVORVor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren's Disease Clinical Study at ACR Convergence 2025GlobeNewswireBOSTON, Sept.
- 1y agoVORVor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs OfficerGlobeNewswireCAMBRIDGE, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Navid
- 1y agoVORVor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEMGlobeNewswireCAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that 48-week clinical data from the
- 1y agoVORVor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation ForumGlobeNewswireCAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a
- 1y agoVORVor Bio Appoints Adi Osovsky, S.J.D. as General CounselGlobeNewswireCAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Adi Osovsky,
- 1y agoPRTCVORPureTech Health plc – Half-Year ReportBusiness WireAchieved meaningful progress toward key value inflection points across our diversified portfolio, with multiple programs advancing into or toward late-stage development Launch of Celea Therapeutics continues our
- 1y agoVORTelitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA NephropathyGlobeNewswireResults reinforce telitacicept's potential across multiple autoimmune diseases Data anticipated to be presented at an upcoming medical conference CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Vor Bio
- 1y agoVORVor Bio to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in the
- 1y agoVORVor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireCAMBRIDGE, Mass., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (NASDAQ:VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, between August 4, 2025, and